MX2022014231A - Conjugados de anticuerpo-farmaco que se enfocan a la uparap. - Google Patents
Conjugados de anticuerpo-farmaco que se enfocan a la uparap.Info
- Publication number
- MX2022014231A MX2022014231A MX2022014231A MX2022014231A MX2022014231A MX 2022014231 A MX2022014231 A MX 2022014231A MX 2022014231 A MX2022014231 A MX 2022014231A MX 2022014231 A MX2022014231 A MX 2022014231A MX 2022014231 A MX2022014231 A MX 2022014231A
- Authority
- MX
- Mexico
- Prior art keywords
- uparap
- drug conjugates
- antibody
- conjugates targeting
- adcs
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 4
- 230000008685 targeting Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con conjugados que se enfocan a la uPARAP, en particular conjugados de anticuerpo-fármaco (ADCs) particulares que comprenden anticuerpos monoclonales dirigidos contra la región N-terminal de la uPARAP, y su uso en el suministro de agentes activos a células y tejidos que expresan la uPARAP. La invención se relaciona además con el uso de los ADC en el tratamiento de enfermedades que implican células que expresan la uPARAP, tales como el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201670063 | 2016-02-05 | ||
DKPA201670834 | 2016-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014231A true MX2022014231A (es) | 2022-12-07 |
Family
ID=58108381
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009461A MX2018009461A (es) | 2016-02-05 | 2017-02-03 | Conjugados de anticuerpo-medicamento que se enfocan a la uparap. |
MX2022014231A MX2022014231A (es) | 2016-02-05 | 2018-08-02 | Conjugados de anticuerpo-farmaco que se enfocan a la uparap. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009461A MX2018009461A (es) | 2016-02-05 | 2017-02-03 | Conjugados de anticuerpo-medicamento que se enfocan a la uparap. |
Country Status (23)
Country | Link |
---|---|
US (3) | US10940213B2 (es) |
EP (2) | EP3895736B1 (es) |
JP (2) | JP7125059B2 (es) |
KR (1) | KR20180105155A (es) |
CN (1) | CN108883197B (es) |
AU (1) | AU2017215869B2 (es) |
BR (1) | BR112018015448A2 (es) |
CA (1) | CA3013677A1 (es) |
CY (2) | CY1124280T1 (es) |
DK (2) | DK3895736T3 (es) |
ES (2) | ES2874668T3 (es) |
FI (1) | FI3895736T3 (es) |
HK (1) | HK1258338A1 (es) |
HR (2) | HRP20230505T1 (es) |
HU (2) | HUE054938T2 (es) |
LT (2) | LT3411076T (es) |
MX (2) | MX2018009461A (es) |
PL (2) | PL3411076T3 (es) |
PT (2) | PT3895736T (es) |
RS (2) | RS62115B1 (es) |
RU (1) | RU2740311C2 (es) |
SI (2) | SI3895736T1 (es) |
WO (1) | WO2017133745A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3013677A1 (en) | 2016-02-05 | 2017-08-10 | Rigshospitalet | Antibody-drug conjugates targeting uparap |
IL309336A (en) * | 2021-06-29 | 2024-02-01 | Rigshospitalet | Antibody-drug conjugates comprising humanized antibodies targeting urokinase-type plasminogen activator receptor-related protein |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
JP2004137151A (ja) | 2002-10-15 | 2004-05-13 | Keio Gijuku | 脳腫瘍の治療・診断薬 |
EP2411413B1 (en) * | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
US20150216998A1 (en) * | 2012-01-01 | 2015-08-06 | Ramot At Tel-Aviv University Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
RU2530553C2 (ru) * | 2012-11-07 | 2014-10-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Рекомбинантное однодоменное антитело, способное специфически связывать фактор некроза опухолей человека, и его производные |
CA3013677A1 (en) | 2016-02-05 | 2017-08-10 | Rigshospitalet | Antibody-drug conjugates targeting uparap |
-
2017
- 2017-02-03 CA CA3013677A patent/CA3013677A1/en active Pending
- 2017-02-03 WO PCT/DK2017/050024 patent/WO2017133745A1/en active Application Filing
- 2017-02-03 EP EP21170407.7A patent/EP3895736B1/en active Active
- 2017-02-03 US US16/074,961 patent/US10940213B2/en active Active
- 2017-02-03 HU HUE17706673A patent/HUE054938T2/hu unknown
- 2017-02-03 PL PL17706673T patent/PL3411076T3/pl unknown
- 2017-02-03 SI SI201731354T patent/SI3895736T1/sl unknown
- 2017-02-03 RS RS20210886A patent/RS62115B1/sr unknown
- 2017-02-03 FI FIEP21170407.7T patent/FI3895736T3/fi active
- 2017-02-03 PL PL21170407.7T patent/PL3895736T3/pl unknown
- 2017-02-03 LT LTEP17706673.5T patent/LT3411076T/lt unknown
- 2017-02-03 ES ES17706673T patent/ES2874668T3/es active Active
- 2017-02-03 PT PT211704077T patent/PT3895736T/pt unknown
- 2017-02-03 DK DK21170407.7T patent/DK3895736T3/da active
- 2017-02-03 RU RU2018125309A patent/RU2740311C2/ru active
- 2017-02-03 JP JP2018540376A patent/JP7125059B2/ja active Active
- 2017-02-03 CN CN201780010196.4A patent/CN108883197B/zh active Active
- 2017-02-03 EP EP17706673.5A patent/EP3411076B1/en active Active
- 2017-02-03 PT PT177066735T patent/PT3411076T/pt unknown
- 2017-02-03 SI SI201730857T patent/SI3411076T1/sl unknown
- 2017-02-03 MX MX2018009461A patent/MX2018009461A/es unknown
- 2017-02-03 LT LTEP21170407.7T patent/LT3895736T/lt unknown
- 2017-02-03 BR BR112018015448A patent/BR112018015448A2/pt active Search and Examination
- 2017-02-03 AU AU2017215869A patent/AU2017215869B2/en active Active
- 2017-02-03 KR KR1020187022361A patent/KR20180105155A/ko active Search and Examination
- 2017-02-03 DK DK17706673.5T patent/DK3411076T3/da active
- 2017-02-03 ES ES21170407T patent/ES2946073T3/es active Active
- 2017-02-03 RS RS20230401A patent/RS64219B1/sr unknown
- 2017-02-03 HU HUE21170407A patent/HUE061880T2/hu unknown
- 2017-02-03 HR HRP20230505TT patent/HRP20230505T1/hr unknown
-
2018
- 2018-08-02 MX MX2022014231A patent/MX2022014231A/es unknown
-
2019
- 2019-01-16 HK HK19100706.4A patent/HK1258338A1/zh unknown
-
2021
- 2021-02-03 US US17/166,177 patent/US11819552B2/en active Active
- 2021-07-01 CY CY20211100587T patent/CY1124280T1/el unknown
- 2021-07-19 HR HRP20211152TT patent/HRP20211152T1/hr unknown
-
2022
- 2022-01-13 JP JP2022003970A patent/JP7304595B2/ja active Active
-
2023
- 2023-05-30 CY CY20231100254T patent/CY1126032T1/el unknown
- 2023-10-11 US US18/485,460 patent/US20240131179A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
MX2022008184A (es) | Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer. | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
MY189113A (en) | Eribulin-based antibody-drug conjugates and methods of use | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
WO2017219029A8 (en) | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS | |
MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
AU2015219495B2 (en) | Disease therapy by inducing immune response to Trop-2 expressing cells | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
MX2017011794A (es) | Composiciones y metodos para diagnosticos y tratamiento del cancer. | |
PH12020551447A1 (en) | Antibodies | |
EP4335851A3 (en) | Pharmaceutical formulations and methods of use thereof | |
CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
PH12020550035A1 (en) | Universal abt compounds and uses thereof | |
BR112021025699A2 (pt) | Anticorpos anti-mesotelina e imunoconjugados dos mesmos | |
FR3096259B1 (fr) | conjugués anticorps-médicament et leur utilisation en thérapie | |
MX2020005473A (es) | Anticuerpos humanizados que se dirigen al factor tisular humano. | |
MX2020002802A (es) | Anticuerpos de cadena pesada que se unen a ectoenzimas. | |
PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof |